Research Solutions
For The Health Industry
Research solutions
for the health industry
Research solutions
for the health industry
Research Solutions
For The Health Industry
Research solutions
for the health industry
Research solutions
for the health industry
November 2019 - Present
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Moderate to-Severe Atopic Dermatitis.
Febrero 2020 - Present
A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy, Safety, and Tolerability of BLU- for the Treatment of Chronic Pruritis in Adult Subjects with Atopic Dermatitis.
March 2020 - Present
A rambdomized, Double Blind Placebo- controlled study to asses the efficacy and safety of Nemolizumab in subjects with Prurigo Nodularis.
May 2019 - Present
Galderma, Phase III Pivotal Study and Open Label Extension to Assess the Efficacy and Safety of Nemolizumab in Moderate to Severe Atopic Dermatitis Subjects and Associated Pruritus.
March 2019 - Present
RE; GD-268-001.
A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 268 and Clindamycin Phosphate Topical Lotion, 1% in Subjects with Acne Vulgaris.
February 2017 - January 2018
71542613.
Open-Label Safety to Assess the Multiple Dose Pharmacokinetics and Potential for Adrenal Suppression Following Topical Treatment with “Halobetasol Propionate 0.05% Topical Spray” (Sun Pharmaceuticals Industries Limited) in Patients with Moderate to Severe Atopic
February 2017 - January 2018
71542611.
Randomized, Double-Blind, Vehicle Controlled, Parallel Design, Multiple Site Clinical Study to Evaluate the Efficiency and Safety of “Halobetasol Propionate 0.05% Topical Spray” (Sun Pharmaceuticals Industries Limited) in Patients with Moderate to Severe.
February 2016 - February 2017
SC1402.
Clinical, Randomized, Multi-Center, Placebo Controlled Study to Evaluate the Efficacy and Safety of 1.5 Milligram and/or Kilogram Per Day of Sarecycline Compared to Placebo in the Treatment of Vulgaris.
September 2014 - January 2015
CIM003JG.
Chugai Pharmaceutical, Phase II, Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of CIM331 in Atopic Dermatitis Patients Who Are Inadaquately Controlled or Intolerant to Topical Therapy.
June 2008 - April 2009
M10-315 ABBOTT.
Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects.
April 2008 - October 2011
M10-016 ABBOTT.
Phase III, Multi-Center, Open Label Continuation Study in Moderate to Severe Plaque Psoriasis in Subjects Who Completed a Proceeding Psoriasis Study with ABT-874.
January 2008 - June 2009
M06-890 ABBOTT.
Phase III, Multi-Center, Randomized, Double Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis.
February 2004 - February 2006
Multi-Center, Open Label, Perspective Studies to Evaluate the Effectiveness and Safety of Etanercept in the Treatment in Psoriasis.
August 1998
M.Muhart & M.Rendon & A.Pedrozo III Tazorac for Treatment of Psoriasis.
August 1998
M.Muhart & M.Rendon & A.Pedrozo III Lentigines Survey & Treatment; Herbal Cream vs. Placebo on Hands.
August 1998
M.Muhart & M.Rendon & A.Pedrozo III Lentingines Treatment; Herbal Cream vs. Hydroquinone Cream 2% on Hands.
February 1992
M.Rendon & A.Pedrozo III Use of Alpha Hydroxyl Acids on Lentingines.
August 1991
Soto & Pedrozo. Monoclonal Antibodies in the Diagnosis of Leishmaniasis.
August 1990
Sexually Transmitted Diseases.
April 1989
Dermatoses in Colombian Soldiers.
April 1988
Etiology & Management of Leg Ulcers.
We are a medical center dedicated to the study, diagnosis, and treatment of skin and hair diseases. Our greatest commitment is to improve the health and beauty of the skin ultimately to improve your life. We offer all clinical diagnoses, procedures, and cosmetic treatments for the skin and hair.
During the course of our studies, patients will be in direct contact with our team of dermatologists and other health professionals with the purpose of giving our patients the best possible care while our team conducts medical research.
If you have any questions about your appointment, please reach out and follow-up and we will make any arrangements so the study will continue and finish successfully.
